EA200970932A1 - Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа - Google Patents

Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа

Info

Publication number
EA200970932A1
EA200970932A1 EA200970932A EA200970932A EA200970932A1 EA 200970932 A1 EA200970932 A1 EA 200970932A1 EA 200970932 A EA200970932 A EA 200970932A EA 200970932 A EA200970932 A EA 200970932A EA 200970932 A1 EA200970932 A1 EA 200970932A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyridopyrimidinonoves
methods
treatment
application
pi3k alpha
Prior art date
Application number
EA200970932A
Other languages
English (en)
Other versions
EA020022B1 (ru
Inventor
Питер Лэмб
Дэвид Мэттьюз
Original Assignee
Экселиксис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Экселиксис, Инк. filed Critical Экселиксис, Инк.
Publication of EA200970932A1 publication Critical patent/EA200970932A1/ru
Publication of EA020022B1 publication Critical patent/EA020022B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Настоящее изобретение обеспечивает способы лечения рака путем введения соединения формулы (I), необязательно в виде его фармацевтически приемлемой соли, сольвата и/или гидрата в сочетании с другими способами лечения рака.
EA200970932A 2007-04-10 2008-04-09 Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k-альфа EA020022B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92289907P 2007-04-10 2007-04-10
PCT/US2008/004573 WO2008124161A1 (en) 2007-04-10 2008-04-09 Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha

Publications (2)

Publication Number Publication Date
EA200970932A1 true EA200970932A1 (ru) 2010-04-30
EA020022B1 EA020022B1 (ru) 2014-08-29

Family

ID=39627802

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970932A EA020022B1 (ru) 2007-04-10 2008-04-09 Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k-альфа

Country Status (32)

Country Link
US (1) US8513266B2 (ru)
EP (1) EP2139484B9 (ru)
JP (3) JP2010523670A (ru)
KR (1) KR101626435B1 (ru)
CN (2) CN101715345A (ru)
AU (1) AU2008236562B2 (ru)
BR (1) BRPI0810206A2 (ru)
CA (1) CA2683641C (ru)
CO (1) CO6251254A2 (ru)
CR (1) CR11100A (ru)
DK (1) DK2139484T3 (ru)
DO (1) DOP2009000243A (ru)
EA (1) EA020022B1 (ru)
EC (1) ECSP099724A (ru)
ES (1) ES2430614T3 (ru)
HK (1) HK1139863A1 (ru)
HN (1) HN2009003002A (ru)
HR (1) HRP20130688T1 (ru)
IL (1) IL201284A (ru)
MA (1) MA31358B1 (ru)
ME (1) ME00936B (ru)
MX (1) MX2009010930A (ru)
MY (1) MY150697A (ru)
NZ (1) NZ580110A (ru)
PL (1) PL2139484T3 (ru)
PT (1) PT2139484E (ru)
RS (1) RS52939B (ru)
SI (1) SI2139484T1 (ru)
TN (1) TN2009000400A1 (ru)
UA (1) UA100979C2 (ru)
WO (1) WO2008124161A1 (ru)
ZA (1) ZA200906764B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200726767A (en) * 2005-07-04 2007-07-16 Astrazeneca Ab Chemical compounds 2
NZ594628A (en) * 2005-10-07 2013-04-26 Exelixis Inc PYRIDOPYRIMIDINONE INHIBITORS OF PI3Ka
CA2623768C (en) * 2005-10-07 2016-04-12 Exelixis, Inc. N-(3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
WO2008021389A2 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
SA08280783B1 (ar) * 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
SI2139484T1 (sl) 2007-04-10 2013-10-30 Exelixis, Inc. Postopki za zdravljenje raka s pirido pirimidin PI3K alfa inhibitorji
ME00937B (me) * 2007-04-11 2012-06-20 Exelixis Inc Kombinovane terapije koje sadrže hinoksalinske inhibitore pi3k-alfa za upotrebu u liječenju kancera
WO2010022126A1 (en) 2008-08-20 2010-02-25 Schering Corporation Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2010022125A1 (en) 2008-08-20 2010-02-25 Schering Corporation Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
EP2326627A1 (en) 2008-08-20 2011-06-01 Schering Corporation Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
EP2326626B1 (en) * 2008-08-20 2013-10-16 Merck Sharp & Dohme Corp. Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8901137B2 (en) 2010-02-09 2014-12-02 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
US20130156768A1 (en) * 2010-08-26 2013-06-20 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with braf inhibitors for the synergistic treatment of proliferative diseases
US9670212B2 (en) 2010-09-14 2017-06-06 Exelixis, Inc. Inhibitors of PI3K-delta and methods of their use and manufacture
WO2012065019A2 (en) 2010-11-12 2012-05-18 Exelixis, Inc. Pyridopyrimidinone inhibitors of p13k alpha
WO2012158960A2 (en) * 2011-05-17 2012-11-22 H. Lee Moffitt Cancer Center & Research Institute, Inc. Melanocortin 1 receptor ligands and methods of use
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
CN104010494B (zh) * 2011-07-28 2017-07-04 霍夫曼-拉罗奇有限公司 Pik3ca h1047r敲入非人动物乳腺癌模型
WO2013056067A1 (en) * 2011-10-13 2013-04-18 Exelixis, Inc. Compounds for use in the treatment of basal cell carcinoma
US20140303172A1 (en) 2011-11-01 2014-10-09 Exelixis, Inc. Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Lymphoproliferative Malignancies
EP2776837A4 (en) * 2011-11-11 2015-05-20 Intellikine Llc COMBINATION OF KINASEINHIBITORS AND THEIR USE
EP2797628A4 (en) 2011-12-27 2015-07-29 Kadmon Corp Llc METHODS OF TREATING BREAST CANCER NOT RESPONDING TO TRASTUZUMAB
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
CN104797267A (zh) 2012-06-26 2015-07-22 德玛医药 使用卫康醇、二乙酰二脱水卫矛醇、二溴卫矛醇或类似物或其衍生物治疗具有基因多型性或ahi1失调或突变患者的抗酪氨酸激酶抑制剂的恶性肿瘤的方法
US8980259B2 (en) * 2012-07-20 2015-03-17 Novartis Ag Combination therapy
PT2882440T (pt) 2012-08-07 2019-04-23 Array Biopharma Inc Combinações farmacêuticas compreendendo um inibidor de braf, um inibidor de egfr e opcionalmente um inibidor de pi3k-alfa
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
GEP20217234B (en) * 2016-08-15 2021-03-25 Pfizer Pyridopyrimdinone cdk2/4/6 inhibitors
JP7027699B2 (ja) * 2017-05-09 2022-03-02 住友ゴム工業株式会社 タイヤトレッドおよびタイヤ
CA3094431C (en) 2018-03-19 2023-06-27 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition including sodium alkyl sulfate
MX2022001863A (es) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Metodos para tratar los tumores del estroma gastrointestinal.
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
WO2021119242A1 (en) * 2019-12-10 2021-06-17 The Trustees Of Indiana University Replication protein a (rpa)-dna interaction inhibitors
IL293864A (en) 2019-12-30 2022-08-01 Deciphera Pharmaceuticals Llc Preparations of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3- phenylurea
LT4084778T (lt) 2019-12-30 2024-01-25 Deciphera Pharmaceuticals, Llc Amorfinės kinazės inhibitoriaus vaistinės formos ir jų panaudojimo būdai
KR102195221B1 (ko) 2019-12-31 2020-12-24 서울대학교산학협력단 포스파티딜이노시톨 3-키나아제 억제제 및 프로그램화 세포 사멸 단백질 1 억제제를 포함하는, 삼중음성 유방암의 방사선 병용 치료용 약학적 조성물
CN111358952B (zh) * 2020-04-15 2022-03-15 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种抗肿瘤药物组合物及其制剂和应用
WO2023092104A1 (en) * 2021-11-18 2023-05-25 Onconova Therapeutics, Inc. Methods and compositions for treating cancer
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
EP1521747B1 (en) * 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
JP2007523151A (ja) * 2004-02-18 2007-08-16 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ２−（ピリジン−３−イルアミノ）−ピリド［２，３−ｄ］ピリミジン−７−オン
WO2005105801A1 (en) * 2004-05-04 2005-11-10 Warner-Lambert Company Llc Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents
WO2007004698A1 (ja) * 2005-07-06 2007-01-11 Sbc Corporation 漏洩電流検出装置及び漏洩電流検出方法
CA2623768C (en) * 2005-10-07 2016-04-12 Exelixis, Inc. N-(3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
AU2006302148B2 (en) * 2005-10-07 2012-12-06 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kalpha
NZ594628A (en) 2005-10-07 2013-04-26 Exelixis Inc PYRIDOPYRIMIDINONE INHIBITORS OF PI3Ka
WO2008021389A2 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
PT2074122E (pt) * 2006-09-15 2011-08-24 Pfizer Prod Inc Compostos de pirido(2,3-d)-pirimidinona e sua utilização como inibidores de pi3
SI2139484T1 (sl) 2007-04-10 2013-10-30 Exelixis, Inc. Postopki za zdravljenje raka s pirido pirimidin PI3K alfa inhibitorji
US20100209340A1 (en) 2007-04-11 2010-08-19 Buhr Chris A Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of p13k-alpha for the treatment of cancer
CA2683784A1 (en) 2007-04-11 2008-10-23 Exelixis, Inc. Pyrido[2,3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
ME00937B (me) * 2007-04-11 2012-06-20 Exelixis Inc Kombinovane terapije koje sadrže hinoksalinske inhibitore pi3k-alfa za upotrebu u liječenju kancera
WO2010039740A1 (en) * 2008-09-30 2010-04-08 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors

Also Published As

Publication number Publication date
NZ580110A (en) 2012-06-29
PT2139484E (pt) 2013-10-31
US8513266B2 (en) 2013-08-20
HN2009003002A (es) 2014-03-24
IL201284A0 (en) 2010-05-31
ME00936B (me) 2012-06-20
AU2008236562A1 (en) 2008-10-16
KR20100016354A (ko) 2010-02-12
CN102727498A (zh) 2012-10-17
PL2139484T3 (pl) 2013-12-31
TN2009000400A1 (en) 2010-12-31
ES2430614T3 (es) 2013-11-21
SI2139484T1 (sl) 2013-10-30
KR101626435B1 (ko) 2016-06-01
ZA200906764B (en) 2010-08-25
EP2139484B1 (en) 2013-07-17
CO6251254A2 (es) 2011-02-21
CN102727498B (zh) 2016-08-03
MY150697A (en) 2014-02-28
EA020022B1 (ru) 2014-08-29
EP2139484B9 (en) 2014-06-11
BRPI0810206A2 (pt) 2014-10-21
RS52939B (en) 2014-02-28
US20100209420A1 (en) 2010-08-19
CA2683641C (en) 2016-08-16
ECSP099724A (es) 2010-03-31
HRP20130688T1 (en) 2013-09-30
JP2010523670A (ja) 2010-07-15
EP2139484B8 (en) 2013-08-21
IL201284A (en) 2016-06-30
HK1139863A1 (en) 2010-09-30
CR11100A (es) 2010-01-19
WO2008124161A1 (en) 2008-10-16
EP2139484A1 (en) 2010-01-06
DOP2009000243A (es) 2010-10-31
JP2014139217A (ja) 2014-07-31
CN101715345A (zh) 2010-05-26
AU2008236562B2 (en) 2013-11-07
MA31358B1 (fr) 2010-05-03
MX2009010930A (es) 2010-01-20
CA2683641A1 (en) 2008-10-16
UA100979C2 (ru) 2013-02-25
JP2014034576A (ja) 2014-02-24
DK2139484T3 (da) 2013-10-21

Similar Documents

Publication Publication Date Title
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
EA201390085A1 (ru) Композиции ингибиторов киназ для лечения рака
TR201900306T4 (tr) Mek inhibitörlerini kullanma yöntemleri.
EA200970856A1 (ru) Ингибиторы пути хеджхога
EA201500300A1 (ru) Способы применения с-мет-модуляторов
TW200738725A (en) Unsaturated mTOR inhibitors
CY1111721T1 (el) Ακυλαμινοπυραζολια ως αναστολεις fgfr
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
AR057295A1 (es) Combinaciones y procedimientos para usar un compuestos de indolinona
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX2010010300A (es) Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
PH12016502353A1 (en) Pharmaceutical composition
UY33221A (es) MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
TW201613577A (en) Pharmaceutical combinations
EA200900691A1 (ru) Применение ингибиторов iap для лечения острого миелоидного лейкоза
ATE543492T1 (de) Behandlung von lungenkrebs
MX2010004967A (es) Uso de inhibidor de cfms para el tratamiento y la prevención del cancer de hueso, así como la perdida osea y el dolor de hueso asociados con el cancer de hueso.
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
EA200901062A1 (ru) Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств
CY1114609T1 (el) Μεθοδοι θεραπειας καρκινου χρησιμοποιωντας αναστολεις p13k αλφα με βαση πυριδοπυριμιδινονη

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU